Alnylam Pharma (ALNY) says Revuiran deaths statistically significant
- European stocks hit three-week low as Trump reality sets in
- Unease over Trump sends dollar to one-and-half month low
- Oil falls as signs of U.S. output rise overshadows OPEC-led cuts
- Morgan Stanley Upgrades Dish Network (DISH) to Overweight
- Walgreens Boots Alliance (WBA) Said to Face Antitrust Concern for Rite Aid (RAD) Fix - Bloomberg
Get access to the best calls on Wall Street with StreetInsider.com's Ratings Insider Elite. Get your Free Trial here.
Alnylam Pharma (NASDAQ: ALNY) says Revuiran deaths statistically significant.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Minerva Neurosciences (NERV) Reports Additional Data Analyses From Phase IIb Trial of MIN-101 in Schizophrenia
- CombiMatrix (CBMX) Presenting Study Suggesting Genomic Alterations Decrease in Frequency and Severity from Conception Through Childhood
- BTIG Says Synergy's (SGYP) Trulance Low Incidence of Side Effects the Key Differentiator
Create E-mail Alert Related CategoriesFDA
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!